A0306
Title: Impact of new technology diffusion on the costs of renal cell cancer
Authors: Ya-Chen Tina Shih - University of Texas MD Anderson Cancer Center (United States) [presenting]
Abstract: The impact of new oncologic technologies on the costs of renal cell cancer (RCC) is examined. We used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database and employed both prevalence and incidence costing approaches. We conducted longitudinal analysis of cost data per patient per month (PPPM) for a prevalence cohort of patients to determine which category of new technology (surgery, radiation, or chemotherapy) was the major cost driver for RCC. We then applied the incidence costing approach to estimate cost related to RCC by care phases (initial, continuing, and terminal) and compared costs between two incidence cohorts to examine how new technology affected RCC costs over time. After controlling for demographic factors, clinical characteristics, neighborhood socioeconomic status, and time trend, we found that rising PPPM costs was driven primarily by new technologies in chemotherapy. Incidence-based analysis showed the annual cost (2018 US\textdollar) for distant stage RCC patients diagnosed between 2002 and 2006 was \textdollar51,639, \textdollar19,025, \textdollar76,603, and \textdollar29,045, for initial, continuing (year 1), terminal (died from RCC), and terminal (died from other causes) care phase, respectively. Costs increased to \textdollar70,703, \textdollar34,716, \textdollar107,989, and \textdollar47,538, respectively, for the incidence cohort diagnosed between 2007 and 2011.
